Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc.
Xencor, Inc.
Nuvectis Pharma, Inc.
Pfizer
Tizona Therapeutics, Inc
Novartis
Kura Oncology, Inc.
AstraZeneca
Coherus Oncology, Inc.
National Institutes of Health Clinical Center (CC)
Genentech, Inc.
DEKA Biosciences
Columbia University
Astellas Pharma Inc
Inhibrx Biosciences, Inc
Celldex Therapeutics
AO GENERIUM
Aurigene Discovery Technologies Limited
Corvus Pharmaceuticals, Inc.
Canadian Cancer Trials Group
AvenCell Therapeutics, Inc.
Bristol-Myers Squibb
Quadriga Biosciences, Inc.
Imperial College London
Syndax Pharmaceuticals
Pfizer
Weill Medical College of Cornell University
Novartis
Syndax Pharmaceuticals
Celgene
Osaka University
National Institutes of Health Clinical Center (CC)
University of Chicago
National Institutes of Health Clinical Center (CC)
Celldex Therapeutics
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Northwestern University
Medical University of South Carolina
Santa Maria Biotherapeutics
Memorial Sloan Kettering Cancer Center
Northwestern University
Valerio Therapeutics
Valerio Therapeutics
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
University of Chicago
National Cancer Institute (NCI)
Altor BioScience
National Cancer Institute (NCI)